Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials.
CONCLUSIONS: Baricitinib significantly improved symptoms in patients with moderate-to-severe AD.
CLINICALTRIALS.GOV IDENTIFIERS: NCT03334396 (BREEZE-AD1) and NCT03334422 (BREEZE-AD2).
PMID: 33222559 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
More News: Corticosteroid Therapy | Dermatitis | Dermatology | Eczema | Itchiness | Pain | Skin | Sleep Disorders | Sleep Medicine